User

Welcome, Guest. Please login or register.
April 24, 2024, 12:16:22 pm

Login with username, password and session length


Forums Index

Stats

Members
  • Total Members: 37651
  • Latest: Toropi_
Stats
  • Total Posts: 773280
  • Total Topics: 66347
  • Online Today: 387
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 2
Guests: 335
Total: 337

Search

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.
« previous next »
Pages: [1]   Go Down

Author Topic: Biktarvy Plus Pifeltro for People With Multidrug-Resistant HIV  (Read 3864 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,385
  • Threads: @jim16309
    • Social Media: Threads
Biktarvy Plus Pifeltro for People With Multidrug-Resistant HIV
« on: May 13, 2023, 03:23:49 am »
Very small study but good results for those with Multidrug-Resistant HIV.

POZ.com article https://www.poz.com/article/biktarvy-plus-pifeltro-option-people-multidrugresistant-hiv

In Short:

Quote
An all-oral regimen of Biktarvy plus Pifeltro maintained viral suppression in people with highly drug-resistant HIV who switched from an older combination regimen, according to a small study published in the journal AIDS.

The study included 20 men, almost all white, who had a median age of 65 years and had been living with HIV for a median of 37 years.

All participants in this open-label study switched from the Odefsey combination pill (rilpivirine/tenofovir alafenamide/emtricitabine) plus Tivicay (dolutegravir) to the Biktarvy coformulation (bictegravir/tenofovir alafenamide/emtricitabine) plus Pifeltro (doravirine).

The participants had documented resistance to protease inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and/or NNRTIs but no known resistance to rilpivirine or doravirine and no K65R or T69 mutations.

At 48 weeks after the switch, 100% of participants still had a viral load below 50
.
Logged
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads
Pages: [1]   Go Up
« previous next »
 

Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.